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Members of the cytochrome P450 monooxygenase family CYP268 are found across a broad 
range of Mycobacterium species including the pathogens Mycobacterium avium, M. 
colombiense, M. kansasii and M. marinum. CYP268A2, from M. marinum, which is the first 
member of this family to be studied, was purified and characterised. CYP268A2 was found to 
bind a variety of substrates with high affinity, including branched and straight-chain fatty acids 
(C10-C12), acetate esters, and aromatic compounds. The enzyme was also found to bind 
phenylimidazole inhibitors but not larger azoles, such as ketoconazole. The monooxygenase 
activity of CYP268A2 was efficiently reconstituted using heterologous electron transfer 
partner proteins. CYP268A2 hydroxylated geranyl acetate and trans-pseudoionone at a 
terminal methyl group to yield (2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate and 
(3E,5E,9E)-11-hydroxy-6,10-dimethylundeca-3,5,9-trien-2-one, respectively. The X-ray 
crystal structure of CYP268A2 was solved to a resolution of 2.0 Å with trans-pseudoionone 
bound in the active site. The overall structure was similar to that of the related phytanic acid 
monooxygenase CYP124A1 enzyme from Mycobacterium tuberculosis, which shares 41 % 
sequence identity. The active site is predominantly hydrophobic but includes the Ser99 and 
Gln209 residues which form hydrogen bonds with the terminal carbonyl group of the 
pseudoionone. The structure provided an explanation on why CYP268A2 shows a preference 
for shorter substrates over the longer chain fatty acids which bind to CYP124A1 and the 




ArR, a ferredoxin reductase from Novosphingobium aromaticivorans; BSTFA-TMSCl, N,O-
bis(trimethylsilyl) trifluoroacetamide and trimethylsilylchloride; CYP Cytochrome P450 
enzyme; DTT, dithiolthreitol; EMM, E. coli minimal media; FAD, flavin adenine dinucleotide; 
FFFAS, Fold and Function Assignment System; IPTG, Isopropyl β-D-1-
thiogalactopyranoside; LB, Lysogeny broth (also known as Luria or Lennox Broth); MAC, 
Mycobacterium avium complex; MRSAD, Molecular Replacement Single Wavelength 
Anomalous Diffraction; MTBC, Mycobacterium tuberculosis complex; NAD(P)H, reduced 
nicotinamide adenine dinucleotide (phosphate); SOC, Super Optimal broth with Catabolite 
repression; Tdx, terpredoxin (a ferredoxin from Pseudomonas sp); PCR, polymerase chain 
reaction; PDIM, phthiocerol dimycocerosates; PE-PGRS, proline glutamate (PE) polymorphic 
GC-rich sequence proteins.  
Introduction 
Cytochrome P450 (CYP) enzymes are a family of heme monooxygenases, capable of 
catalysing the insertion of a single oxygen atom, derived from molecular oxygen, into an inert 
carbon-hydrogen bond of a wide range of organic substrates [1]. Cytochrome P450 enzymes 
are ubiquitous in nature, with genes in humans [2], other animals [3], plants and many fungal 
and bacterial species. CYP enzymes perform both anabolic (building up metabolites) and 
catabolic (breaking them down) processes, making them key enzymes in secondary and 
xenobiotic metabolism [2] and targets for antibacterial drug design [4]. They have also been 
shown to perform a variety of reactions, most commonly hydroxylation but also further 
oxidation, C-C bond formation, desaturation and epoxidation, using electrons ultimately 
sourced from NAD(P)H [5]. Individual CYPs often show high specificity for their substrate 
and selectivity in the site of the target molecule where the oxidation takes place [6, 7]. The 
catalytic activity of CYP enzymes is dependent on the delivery of the two electrons to the heme 
in two separate, highly regulated steps. In bacterial species, this is most often achieved by the 
combination of two cytosolic electron transfer partners, a flavin-adenine dinucleotide (FAD) 
containing ferredoxin reductase and an iron-sulfur ferredoxin, together known as a Class 1 
electron transfer system [8].  
Upon sequencing of the Mycobacterium tuberculosis genome [9], the high number of 
CYP genes found (20) was unprecedented for a bacterial species at the time (in contrast, 
Escherichia coli has none). As a result the CYPome of M. tuberculosis has been a target for 
inhibitory drug design in the years since [10]. Due to increasing numbers of drug resistant and 
multi-drug resistant strains, and a disease profile that overlaps with that of HIV/AIDS, M. 
tuberculosis continues to be responsible for large scale loss of life [11, 12]., Approximately 
one third of the global population has the latent form of tuberculosis according to WHO 
estimates, with over 10 million new cases of the active form each year [13]. Members of the 
Mycobacterium family are widespread and range from soil-bacteria to human pathogens. 
Mycobacterium marinum M, a pathogen of frogs and fish, is a close relative of both M. 
tuberculosis H37Rv (85 % nucleotide identity) and also the pathogenic species Mycobacterium 
ulcerans Agy99 (97 %) [14]. M. ulcerans is responsible for the Buruli ulcer (also referred to 
as the Daintree or Bairnsdale ulcer) which is a skin disease primarily found in tropical areas, 
most often in central and western Africa [15]. M. marinum has 47 individual CYP encoding 
genes in its genome while M. ulcerans has 24. M. marinum is thought to resemble a common 
ancestor of the more pathogenic Mycobacterium species, with a genome that has not undergone 
the extensive reduction by gene deletion and pseudogene formation that characterises the 
genome of M. tuberculosis and, to a lesser extent, M. ulcerans [14, 15]. M. marinum is a more 
versatile pathogen, primarily affecting aquatic life but also capable of surviving in a human 
host as the causal agent of aquarium granuloma, and, unlike the human pathogens, of persisting 
outside of its host entirely [14, 16]. It has been shown to adapt to a variety of hosts, altering 
virulence mechanisms to suit, including the differential regulation of polyketide lipids, and 
sterol utilisation [16]. Thus the larger genome of M. marinum provides both increased 
redundancy, with a smaller percentage of essential genes than M. tuberculosis, but also 
increased adaptability. This is part of a common trend, where the number of CYP genes in 
Mycobacterium species decreases as the organism environment changes from soil living 
mycobacteria (average of 50 CYPs) to a human pathogen (average of 19) [17].  
Where there are direct counterparts for M. marinum CYPs in M. tuberculosis, the roles 
of the majority are still unknown. Several of the enzymes are reported as cholesterol oxidases, 
including some that are essential for viability in vitro. The deletion of the CYP125A1 enzyme 
together with CYP124A1 leads to a build-up of the intermediate cholest-4-en-3-one and the 
inhibition of the organism [18]. The cholesterol degradation activity of CYP125A1 has been 
linked to the density of the mycobacterial cell wall, increasing the mass of phthiocerol 
dimycocerosates (PDIM) [19]. The Mycobacterial cell envelope is distinguished by several 
features, most prominently the additional layer of long chain fatty acids known as mycolic acid 
covalently bound to the peptidoglycan of the cell wall [20]. PDIM and other multiple methyl-
branched long chain fatty acids further increase the density and thickness of this layer. Lipid 
metabolism is another common role of bacterial CYPs, and in M. tuberculosis, CYP124A1 has 
been shown to hydroxylate phytanic acid and similar fatty acid compounds [21]. The majority 
of M. tuberculosis CYPs, however, have either resisted recombinant expression efforts, or have 
not shown activity when screened against libraries of common substrates, leaving uncertainty 
about the roles of the Mycobacterial CYPome as a whole. Even where the substrate and product 
is known, it is not well understood how these play into the metabolism of the organism. For 
example, while M. tuberculosis is known to have no sterol synthesis pathway, CYP51B1, a 
highly conserved sterol-α-demethylase, is present [22]. The current understanding of M. 
tuberculosis virulence points to specialised areas such as mycolic acid synthesis, other lipid 
metabolism and cholesterol catabolism as critical [23], in the second two of which there is 
evidence for CYP involvement.  
Analogues of many of these characterised CYP proteins are present in other species of 
Mycobacteria. For example, CYP51B1 is found in a highly conserved operon in 
Mycobacterium smegmatis MC2 155 and M. tuberculosis, containing a CYP123 enzyme, a 
ferredoxin, a TetR regulator and an ORF of unknown function [24]. The same operon is 
conserved in M. marinum M and M. ulcerans Agy99. The conservation of various CYPs 
outside of the Mycobacterium tuberculosis complex (MTBC) has been taken as evidence that 
they perform general or housekeeping roles, while conservation only in M. bovis or mammalian 
pathogens has led to a suggested role in virulence or human-infectivity [25]. The 
characterisation of CYP enzymes present only in non-MTBC species has been attempted for 
various reasons. Some were potential catalysts for reactions of biosynthetic interest, such as 
CYP153A16, from M. marinum, which was found like other members of the CYP153 family 
to oxidise medium-chain alkanes [7]. CYP151A1 in M. smegmatis MC2 155 and CYP151A2 
from Mycobacterium sp strain RP1, were identified in the effort to understand the ability of the 
respective organisms to utilise pyrrolidine and piperidine as sole carbon sources [26, 27]. Both 
can oxidise secondary amines, catalysing ring opening and allowing further catabolism. In 
addition CYP150 family members from Mycobacterium vanbaalenii PYR-1 have been 
hypothesised to oxidise polycyclic aromatic hydrocarbons, making them a catalyst of interest 
for environmental remediation [28].   
As a result of its larger CYPome, a number of CYPs are found in M. marinum M that 
do not have direct counterparts in either of M. tuberculosis or M. ulcerans, and which may play 
a role in the different pathogenicity of the organism. The enzyme CYP268A2 is one instance 
of this, with only a truncated pseudogene (cyp268A2P) remaining in the M. ulcerans Agy99 
genome, and no relative in M. tuberculosis. It is highly conserved across a broad range of other 
Mycobacterium species and other bacteria. We have performed preliminary structural and 
functional characterisation of this enzyme, with a view to elucidating its role in the metabolism 
of M. marinum and across the Mycobacteria (Mycobacteriaceae) as a whole.  
Experimental 
General  
All organic substrates, derivatisation agents and general laboratory reagents, except where 
otherwise noted, were purchased from Sigma-Aldrich, Alfa-Aesar, VWR International or 
Tokyo Chemical Industry. Antibiotics, detergents, DTT and IPTG were from Astral Scientific. 
Restriction enzymes used for cloning were purchased from New England Biolabs. KOD 
polymerase, used for the PCR steps, and the expression vectors were from Merck-Millipore. 
The following were used as media for cell growth and maintenance: LB (Lysogeny 
Broth); tryptone (10 g), yeast extract (5 g) and NaCl (10 g) per litre; 2xYT contains tryptone 
(16 g), yeast extract (10 g) and NaCl (5 g) per litre; SOC (Super Optimal broth with Catabolite 
repression); tryptone (20 g), yeast extract (5 g), NaCl (0.5 g), KCl (0.2 g), MgCl2 (1 g) and 5 
mL of 40 % glucose per litre; EMM (E. coli minimal media); K2HPO4 (7 g), KH2PO4 (3 g), 
Na3citrate (0.5 g), (NH4)2SO4 (1 g), MgSO4 (0.1 g), 20 % glucose (20 mL) and glycerol (1 % 
v/v) in one litre; Trace elements; 0.74 g CaCl2·H2O, 0.18 g ZnSO4·7H2O, 0.132 g 
MnSO4·4H2O, 20.1 g Na2EDTA, 16.7 g FeCl3·6H2O, 0.10 g CuSO4·5H2O, 0.25 g 
CoCl2·6H2O. Antibiotics were added to the following working concentrations; ampicillin, 100 
µg mL1 and kanamycin, 30 µg mL1.  
UV Visible spectra were recorded on a Varian Cary 5000 at 30 ± 0.5 °C. GC-MS 
analysis was performed using a Shimadzu GC-17A equipped with a QP5050A GC-MS detector 
and DB-5 MS fused silica column (30 m x 0.25 mm, 0.25 µm) or a Shimadzu GC-2010 
equipped with a QP2010S GC-MS detector, AOC- 20i autoinjector, AOC-20s autosampler and 
DB-5 MS fused silica column (30 m x 0.25 mm, 0.25 µm). The injector was held at 250 °C and 
the interface at 280 °C. Column flow was set at 1.5 mL/min and the split ratio was 24. Solvent 
cut time was set to 3 min. For ionone and acetate substrates, the oven was held at 80 °C for 3 
min followed by an increase of 10 °C per min up to 220 °C and a final hold for 3 min. For 4-
phenyltoluene, the initial temperature and hold time were the same but the rate of increase was 
12 °C per min to a maximum of 230 °C, where it was held for 5 min. Preparative HPLC analysis 
was carried out on a Shimadzu system equipped with a DGU-20A5R degasser, 2 x LC-20AR 
pumps, SIL-20AC HT autosampler, SPD-M20A photodiode array detector and a CT0-20AC 
column oven. Separation was performed using an Ascentis Si HPLC column (25 cm × 10 mm 
x 5 μm; Sigma-Aldrich). NMR was performed using an Agilent DD2 spectrometer at 500 MHz 
for 1H and 126 MHz for 13C.  
Sequence alignment performed by ClustalW. Phylogenetic tree drawn using the 
Maximum Likelihood method based on the Jones-Taylor-Thornton (JTT) model with complete 
deletion of missing data. Initial tree(s) for the heuristic search were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using 
a JTT model, and then selecting the topology with superior log likelihood value.  
Recombinant protein expression and purification 
The CYP268A2 gene (Mmar_3761) was amplified by PCR using oligonucleotide primers (vide 
supra). The gene was amplified by 30 cycles of strand separation at 95 ºC for 45 s followed by 
annealing at 55 ºC for 30 s and extension at 68 ºC for 80 s. The genes were cloned into the 
pET26 vector using the appropriate NdeI and HindIII restriction enzymes and the correct 
insertion was checked by Sanger sequencing performed by Australian Genome Research 
Facility Ltd (AGRF). The plasmid was then transformed into Escherichia coli BL21(DE3). 
The transformed E. coli cells were grown on an LBkan plate, and incubated in 2YTkan (1.2 L 
total, in 6 flasks) at 37°C for 5 hours at 160 rpm. Following this, the temperature was reduced 
to 18 °C, the speed to 90 rpm. Benzyl alcohol (0.02 % v/v), ethanol (2 % v/v) and, after 30 
mins, IPTG (0.1 mM) were added to induce protein expression [29]. The growths were 
continued for a further 16 hours before harvesting of the cell pellet by centrifugation (5000 g, 
15 mins). The cells were then resuspended in 50 mM Tris (pH 7.4) with 1 mM DTT (henceforth 
Buffer T), with β-mercaptoethanol (1 mL), TWEEN (1 mL) and glycerol (20 % v/v), to a total 
volume of 200 mL. The resuspended cells were then lysed by sonication (25 cycles of 20:40 
secs on/off, 70 %, 19 mm probe, Sonics Vibra-Cell) while kept on ice. The supernatant was 
isolated from the cell debris by centrifugation (40 000 g, 30 mins) and then loaded onto a DEAE 
Sepharose column, (XK50, 200 mm x 40 mm, GE Healthcare) and eluted with a linear gradient 
of 100 mM to 300 mM KCl in Buffer T. The fractions containing the desired P450 were 
identified by their red colour, and pooled, concentrated using a Vivacell 100 (Sartorius Stedim, 
10 KD membrane), and desalted using a Sephadex G-25 medium grain column (250 mm x 40 
mm) with elution using Buffer T. The protein sample was then loaded onto a further Source-Q 
anion exchange column (XK26, 80 mm x 30 mm, GE Healthcare) and eluted with a gradient 
of 0 to 1 M KCl in Buffer T. Collected fractions were concentrated again by ultrafiltration and 
stored at -20 °C in an equal volume of glycerol, after filtration with a 0.22 µM syringe filter. 
The final A420/A280 ratio was 1.6. 
Before use, the glycerol was removed from CYP268A2 by gel filtration, using a 5 mL 
PD-10 column (GE Healthcare) and elution with Buffer T (without DTT). The extinction 
coefficient for CYP268A2 was determined by CO difference spectra using ε450 = 91 mM
−1 cm−1 
for the reduced CO bound form [30]. The CYP268A2 concentration was determined using ε419 
= 108 ± 7 mM−1 cm−1.  
Spin state shifts and substrate binding titrations  
To determine the extent of substrate binding, CYP268A2 was diluted to ~1 µM in 50 mM Tris 
(pH 7.4) to a volume of 500 µL, and various substrates (100 mM, EtOH or DMSO) were added. 
The absorbance between 600 nm and 250 nm was recorded on the UV spectrophotometer until 
no further spectral change was observed. The high spin percentage was estimated (± 5 %) by 
comparison to a set of spectra, generated by the sum of substrate free ( > 95 % low spin, 418 
nm Soret maximum) and camphor-bound (> 95 % high spin, 392 nm Soret maximum) 
CYP101A1 to the appropriate percentages.  
For substrate binding titrations, CYP268A2 was diluted to 2 µM in 50 mM Tris (pH 
7.4) to a volume of 2.5 mL and 1-3 µL of substrate was added via a Hamilton syringe from 
either 1, 10 and 100 mM (EtOH or DMSO) stock solution, starting from the lowest 
concentration. The peak-to-trough difference in absorbance, between 600 nm and 250 nm, was 
recorded until additional aliquots caused no further spectral change in the Soret band. The 
dissociation constant for that substrate was obtained by fitting the difference in absorbance 
against the substrate concentration to the hyperbolic function:  




where Kd is the binding constant, [S] is the substrate concentration, ΔA the peak-to-trough 
ratio, and ΔAmax the maximum peak-to-trough absorbance. In the instances where the substrate 
exhibited tight binding (Kd < 10 µM, less than five times the concentration of the enzyme), the 
data were instead fitted to the tight-binding quadratic equation: 
∆𝐴 =  𝛥𝐴 ×
[𝐸] + [𝑆] + 𝐾𝑑 − √([𝐸] +  [𝑆] + 𝐾𝑑)2 − 4[𝐸][𝑆] 
2[𝐸]
 
where Kd is the binding constant, [S] is the substrate concentration, ΔA the peak-to-trough 
ratio,  ΔAmax the maximum peak-to-trough absorbance and [E] is the enzyme concentration 
[31]. 
Construction of in vivo systems to support product formation  
To construct whole cell turnover systems, CYP268A2 was cloned into a pRSFDuet vector 
using the NdeI and KpnI sites introduced by PCR. ArR has been cloned into pETDuet 
previously [32]. The terpredoxin gene was purchased (gblock; Integrated DNA Technologies) 
and cloned into pETDuetArR using NcoI and HindIII sites (Supplementary material). The two 
vectors, pRSFDuet containing CYP268A2, and pETDuet, containing Tdx and ArR, were 
transformed into E. coli BL21 cells. The transformed cells were grown overnight on an 
LBamp/kan plate. A colony was picked and grown in 50 mL LBamp/kan for 6 hours at 37 °C and 
110 rpm. It was then cooled to 18 °C and slowed to 90 rpm, with the addition of benzyl alcohol 
(0.02 % v/v) and ethanol (2 % v/v), followed after 30 mins by IPTG (0.1 mM). The culture was 
then left overnight. The cell pellet was harvested by centrifugation (5000 g, 10 min) before 
being resuspended in EMMamp/kan (100 mL). The substrate was then added to 1 mM final 
concentration before shaking at 150 rpm at 30 °C. After 24 hours the turnover was then 
centrifuged (15 min, 5000 g) and the supernatant isolated. Samples (1 mL) of the turnover were 
taken for initial testing via GC-MS at various time points. The samples were extracted into 
ethyl acetate, dried over MgSO4 before resuspension in anhydrous acetonitrile (200 µL). Where 
GC-MS showed product formation, larger scale growths by the same method (200 mL EMM) 
were performed and extracted. The extract was dissolved in 5 % isopropanol:hexane and 
purified by semi-preparative HPLC using an elution gradient of 5 – 10 % isopropanol. The 
chromatogram was monitored at 254 nm. Relevant peaks (as confirmed by GC-MS) were 
collected, pooled and resuspended in deuterated chloroform to allow analysis by NMR.  
In vitro NADH activity assays  
Purified CYP268A2 (0.5 µM) together with the ferredoxin Tdx (5 µM) and ferredoxin 
reductase ArR (0.5 µM) (the purification method of these are reported elsewhere [32, 33]) were 
mixed to a total volume of 1.2 mL in oxygenated 50 mM Tris (pH 7.4), with added catalase 
(120 µg).  The mixture was equilibrated for 2 min at 30 °C before the addition of 320 µM 
NADH (A340 ≈ 2.0). Substrate was then added to a concentration of 0.25 mM. The reaction was 
monitored at 340 nm for the duration. The rate of NADH turnover was calculated by plotting 
the A340 against time, using ε340 = 6.22 µM. Once the reaction was at completion, 1 mL of the 
turnover was extracted into ethyl acetate and analysed by GC-MS as above.  
Crystallography, data collection, data processing and structural determination 
CYP268A2 was further purified by size exclusion chromatography (Enrich SEC Column, 650 
10 x 300 mm) before being concentrated to 30-35 mg mL-1 in Buffer T. The substrate 
pseudoionone (100 mM EtOH, mix of isomers) was added to the protein to a final concentration 
of 1 mM immediately before crystallisation. The initial screening of crystallisation conditions 
was performed by sitting-drop method in 96-well plates with commercially available screening 
conditions (Hampton Research) using 1 µL of both the protein solution and the reservoir 
solution. Crystal conditions were refined using the hanging drop vapour diffusion method, and 
again with 1 µL of both the protein solution and the reservoir solution, equilibrated with a 500 
µL reservoir. Diffraction-quality crystals (plates with dimensions ~150 x 140 x 20 µM, Figure 
S4) were obtained after 2 weeks at 16 °C from the condition containing 0.96 M ammonium 
phosphate, 0.3 M sodium citrate pH 7.0.  They were harvested with a Micromount (MiTeGen) 
and cryo-protected by immersion in Parabar 10312 (Paratone-N, Hampton Research) before 
flash cooling in liquid N2. Data was collected by X-ray diffraction at 100 K on the Australian 
Synchrotron MX1 beamline (360 exposures using 1° oscillations at a wavelength of 0.9537 Å) 
[34]. The data were processed in the space group C2 using XDS [35, 36]. Initial molecular 
replacement phasing was attempted using the modified search model (residues 1-23, 145-152, 
322-337, 244-253 were removed from the surface to improve the search model clashes) from 
PDB entry 2WM4 [21] (CYP124A1 with phytanic acid bound, found by searching the FFAS 
server) with the MRSAD protocol of Auto-Rickshaw [37, 38] using the native dataset.  Within 
the pipeline various programs from the CCP4 program suite [39] were used and the model 
phases were improved by model refinement using CNS [40, 41] and REFMAC5 [42], density 
modification using PIRATE [43] and rebuilding of the model using SHELXE [44], RESOLVE 
[45] and Buccaneer [46], finally refinement of the resulting model using Phenix [47] and 
REFMAC5. The structure was further rebuilt using Coot [48] based on the initial electron 
density maps, with multiple structural refinement iterations using phenix.refine. Composite 
omit maps were generated using the Composite Omit Maps program in Phenix. 
  
Results/Discussion 
Phylogenetic and sequence analysis 
Alongside CYP268A2, genes encoding members of the cytochrome P450 monooxygenase 
CYP268 family are primarily found in other Mycobacterium species. These include 
CYP268A1 from M. avium subsp. paratuberculosis, A3 and B2 from M. smegmatis, and B1 
and C1 from M. vanbaalenii (accession numbers and similarities are listed in Table S1). A 
single member, CYP268A4 is found in Streptomyces bingchengensis. A BLAST search found 
a large number of proteins with high sequence identity (250 results >70 %), almost exclusively 
from other Mycobacterium species (none of the first 250 results were from non-Mycobacteria 
species). CYP268A2 is conserved in Mycobacterium liflandii (98 %) and as a pseudogene in 
M. ulcerans Agy99 (95 %, truncated after 195 residues). A similar gene without truncation is 
found in M. ulcerans subsp. shinshuense (97 %), a clinical isolate from Japan [49]. Close 
analogues are also found in M. avium (78 %), M. colombiense (77 %) and Mycobacterium 
kansasii (85 %), among others. A M. tuberculosis strain TKK-01-0051 contained an analogous 
protein with high sequence similarity (78 %), although there is some suggestion that this strain 
may be misclassified and is better referred to as Mycobacterium colombiense [50]. M. 
colombiense is a member of the Mycobacterium avium complex, and is known to 
opportunistically infect HIV-positive immuno-compromised patients [51].  
The CYP268 family also shares high sequence similarity with the CYP124, CYP125 
and CYP142 families, of which members from M. tuberculosis, M. marinum, M. smegmatis 
and M. vanbaalenii are known (Table S1). In particular CYP268A2 has a sequence similarity 
above 40 % with many members of the CYP124 family. The CYP142B subfamily members 
cluster together (Figure 1), more closely to the 124 and 268 families than to the 142A 
subfamily, suggesting a high degree of overlap between the three families. CYP124A1 from 
M. tuberculosis (with 41 % similarity to CYP268A2), has been characterised as a lipid 
hydroxylase [21] and additionally can oxidise vitamin D3 and other analogues [52]. 
CYP142A1, also from M. tuberculosis, (33 % similarity to CYP268A2), can oxidise 
cholesterol esters [53] and CYP125A1 (40 %) is similarly a cholesterol hydroxylase [54]. 
A sequence alignment (Figure S1) revealed that of the cytochrome P450 commonly 
conserved sequence elements, CYP268A2 retains the glutamate and arginine pair (Glu300, 
Arg303), as well as the phenylalanine residue (Phe364) in the K helix, 7 residues before the 
conserved proximal cysteine at Cys372 [55]. The acid alcohol pair in the enzyme is an aspartate 
(Asp263) and threonine (Thr264) The CYP124A1 family members contain a glutamate 
(Glu270 in CYP124A1) rather than the aspartate found in the CYP268 enzymes (Figure S1).  
The area surrounding putative cyp268 genes is marked by the presence of a highly 
conserved operon (Figure S2), containing a GTPase, a large ribonuclease, two regulatory 
proteins (AcrR and Sir2-like) and a downstream NAD synthetase. Cyp268A2 is flanked on both 
sides by a PE-PGRS gene (glycine rich proteins detected across the Mycobacteria with possible 
roles as antigens [56] or fibronectin-binding [57]). The environments of the cyp124 genes (M. 
marinum and M. tuberculosis) do not have any of these genes but share some similarity with 
each other (Figure S2).   
Characterisation of CYP268A2 and its substrate range 
The CYP268A2 enzyme was produced in E. coli and purified by two ion exchange 
chromatography steps. The protein was tested for the characteristic Soret absorbance, occurring 
when the ferrous form of the CYP enzyme binds CO [58]. CYP268A2 after reduction by 
sodium dithionite and gentle bubbling with CO, shifted almost completely from the resting 
state absorbance at 419 nm to 450 nm, with only a small shoulder (< 5 %) at 420 nm (Figure 
2). The extinction coefficient for the Soret absorbance [58], ε450 = 91 mM cm
-1, was used to 
determine the extinction coefficient for CYP268A2 ε419 = 108 ± 7 mM cm
-1 which was 
henceforth used to determine the concentration of the enzyme.  
As CYP268A2 is the first member of its P450 family to be studied, previously 
characterised family members are not available to give an indication as to the role of the 
enzyme. Based on the similarity to members of the CYP124 lipid-hydroxylase family [21], the 
initial substrates tested on CYP268A2 were branched and straight chain fatty acids and esters 
(Figure 3). A number of these were successful in shifting the majority of the enzyme into the 
high spin form, indicating that they were accommodated by the active site of the enzyme 
(Figure S5). Geranyl acetate (80 % HS) and farnesyl acetate (75 % HS) both induced higher 
spin state shifts in CYP268A2 than undecanoic acid (70 % HS) which was the best performing 
acid substrate (Table 1). Additionally it was discovered a range of aromatic compounds could 
bind the enzyme. 4-phenyltoluene (55 % HS), phenyl acetate (50 % HS) and 
phenylcyclohexane (50 % HS) all successfully induced a Type I Soret shift. The binding 
affinity of CYP268A2 for the substrates that gave the highest spin state shifts was then assessed 
(Figure 4). Farnesol (75 % HS) bound to the enzyme with high affinity, Kd, 0.8 ± 0.2 µM. 
Undecanoic acid gave Kd, 1.1 ± 0.5 µM. Pseudoionone, a linear ionone precursor, gave 80 % 
HS and Kd, 3.6 ± 0.6 µM (as a mixture of isomers). 4-Phenyltoluene also bound tightly, Kd, 13 
± 2.4 µM. Notably the longer substrates preferred by CYP124A1 such as phytanic acid failed 
to induce a significant spin state shift in CYP268A2 (Table S2).  
 The enzyme did not appear to have the strict requirement for branching methyl groups 
at the terminus of the substrate as shown by CYP124A1, with lauric acid (55 % HS) 
outperforming both 11-methyllauric acid (30 % HS) and 10-methyllauric acid (20 % HS), 
although 15-methylhexadecanoic acid (15 %) was more effective than palmitic acid (0 %). The 
binding data suggested the enzyme active site could better accommodate straight chain 
substrates over those with longer bent chains, preferring the trans isomer, geranyl acetate (Kd, 
8.5 ± 1.9 µM), over the cis form, neryl acetate (30 % HS, Kd, 106 ± 29 µM, Figure S7). 
CYP124A1 has additionally been characterised as having cholesterol and vitamin D binding 
activity [52] (as do CYP125 and CYP142 family members [54, 59]).  As a result, CYP268A2 
was tested with a variety of cholesterol and vitamin D analogues, but those gave no or very 
little (0-5 % high spin form) indication of binding. The substrate binding data demonstrates 
that the active site of CYP268A2 is versatile and can accommodate a range of linear and 
aromatic hydrocarbons, terpenes and fatty acids. Some substrates such as farnesol that have 
been reported for CYP124A1 bind well with CYP268A2 but it appears to support a wider range 
of substrate binding.  
Many azole drugs have been reported to bind CYPs as competitive inhibitors, 
coordinating directly to the Fe atom of the heme and generating Type II spectral shifts, shifting 
the Soret band to a higher wavelength rather than to 390 nm which is characteristic of 
displacement of the distal water ligand [60, 61]. These have been proposed as methods for 
inhibiting bacterial growth, particularly in species where CYPs play essential roles [62]. A 
number of possible azole inhibitors were tested with CYP268A2 (Table 2). CYP268A2 gave 
Type II shifts with two of these, 1-phenylimidazole (shifted the Soret maximum to 421 nm) 
and 4-phenylimidazole (shifted the Soret maximum to 423 nm). The binding affinity of these 
to CYP268A2 was assessed by determining the dissociation constant (Figure 4). 1-
Phenylimidzole bound more tightly (Kd, 0.9 ± 0.3 µM) than 4-phenylimidazole (Kd, 4.5 ± 0.6 
µM). The addition of 2-phenylimidazole and other larger azole inhibitors yielded a small Type 
I shift. 
Product characterisation 
As CYP268A2 has no closely located ferredoxin gene in the M. marinum genome, it was 
expressed in E. coli with a variety of electron transfer partners from different organisms (Table 
S3). The pair terpredoxin (2Fe-2S ferredoxin, from a Pseudomonas sp.) and an FAD-containing 
ferredoxin reductase ArR (from Novosphingobium aromaticivorans) were selected (based on 
levels of product formation with geranyl acetate, supplementary material) to enable 
characterisation of the products of the enzyme. In vitro turnovers were used to analyse the 
product formation rate and where product was formed, substrates were scaled up with in vivo 
turnovers to allow characterisation.  
The addition of geranyl acetate to CYP268A2 in vitro gave an NADH consumption rate 
of ~60 nmol.nmolP450-1 min-1 and when extracted and analysed by GC-MS, showed a major 
product (9.5 mins, Figure 5a) with a mass peak of 152.15 (expected mass of hydroxylation 
product is 214.16, 152.12 with loss of the acetate) after 24 hours. To characterise the product, 
large scale in vivo turnovers were performed (Figure 5a). The in vivo major product had a 
slightly different retention time at 9.4 mins and the mass peaks (154.25, 136.20 and others) 
were two mass units higher than those of the in vitro product. The pattern of products in the 
GC trace of the whole-cell turnovers over time combined with mass spectrum peaks suggests 
the major product in vivo was also hydrogenated in addition to the CYP-mediated 
hydroxylation (Supplementary material, Figure S8). HPLC purification of the major product 
followed by NMR analysis identified the metabolite as the terminal hydroxylation product (E)-
8-hydroxy-3,7-dimethyloct-2-en-1-yl acetate (Figure 6 and Supplementary material Figure 
S15). The in vitro turnover experiment with geranyl acetate confirms the hydroxylation is CYP-
mediated while it is likely the hydrogenation was performed by an endogenous E. coli ene 
reductase [63, 64].  
The in vitro turnover of pseudoionone by CYP268A2 had an NADH consumption rate 
of 48 nmol.nmolP450-1 min-1 and a generated a single major product at 16.1 mins with a mass 
peak at 208.1 (expected hydroxylation product at 208.15). Addition of pseudoionone to the in 
vivo CYP/Tdx/ArR system generated a single major product after 24 hours with a retention 
time of 15.9 mins (Figure 5b). Mass peaks of the in vivo product (210.2 and 195.20 and others) 
were again two mass units higher than the in vitro product (Figure S9). The major product from 
the whole-cell turnover was isolated by HPLC and characterised by NMR to be (3E,5E)-11-
hydroxy-6,10-dimethylundeca-3,5-dien-2-one (Figure 6 and Figure S16). Similarly to geranyl 
acetate, the in vivo product has been hydrogenated at the ω-2 alkene in addition to ω 
hydroxylation. The pseudoionone was a mixture of isomers, and there are two substrate peaks 
at 12.0 and 12.7 min (192.15 and 192.20 m/z compared to expected molecular ion peak at 
192.15) which are the cis (3E, 5Z) and trans (3E, 5E) isomer, respectively. In both the in vitro 
and in vivo turnovers the enzyme showed a preference for the trans pseudoionone isomer, 
which was consumed over the course of the turnover, whereas the cis was not.  
A product from the CYP268A2 catalysed oxidation of 4-phenyltoluene was also 
identified by GC-MS (Figure S10). This was assigned as 4-biphenylmethanol by MS 
comparison and GC co-elution experiment with other P450 turnovers [65]. Other substrates, 
including undecanoic acid, neryl acetate, farnesol, farnesyl acetate and geraniol, were tried but 
no product was detected. The selectivity for trans- over cis-pseudoionone and geranyl over 
neryl acetate, which aligns with the binding data, indicates that enzyme prefers the straight 
chain isomer over the bent form. The absence of product for geraniol suggests substrates with 
the acetate ester moiety are favoured. The catalytic turnover rate reported is expected to be 
limited by the use of non-native electron transfer partners, which generally support lower levels 
of oxygenase activity [66]. However the ability of Tdx to support CYP268A2 activity is a 
strong indication that the physiological electron transfer partner may be a [2Fe-2S] ferredoxin. 
Ideally, the native transfer partners of CYP268A2 from M. marinum would be identified. The 
availability of known substrates of CYP268A2 which with have demonstrated product 
formation will facilitate this process.  
 
Crystal structure of pseudoionone-bound CYP268A2 
Crystallisation of both substrate-bound and substrate-free CYP268A2 was attempted. When 
pseudoionone was added before crystallisation, CYP268A2 formed sharp-edged single crystals 
after two weeks and diffraction data was collected to 2.0 Å at the Australian Synchrotron. No 
suitable crystals of the substrate-free form were obtained. The solved structure consists of a 
single polymer chain in the asymmetric unit and the trans (3E, 5E) form of the substrate 
pseudoionone in the active site (PDB code 6BLD). All residues were modelled except the first 
five of the N terminus. Refinement statistics for the structure are located in Table 2. The overall 
fold conforms closely to the canonical P450 fold (Figure 7b). A loop of unstructured residues 
(Pro46 to Phe61) between two β-sheet regions forms an active site ‘cap’ similar to that of 
CYP124A1 [21]. The electron density map shows the pseudoionone is arranged with one of 
the ω methyl groups held directly over the heme (4.3 Å away from the Fe atom). The carbonyl 
group of the substrate interacts with residues from the G helix and the B-C loop, towards the 
apparent exit of the active site (Figure 7a). The residues of the active site that interact directly 
with the carbonyl of pseudoionone, Gln209 and Ser99, sit close enough at 2.8 and 3.4 Å 
respectively, to form hydrogen bonds (Figure 7c). This arrangement provides structural 
justification for the substrate binding preference for oxygen-containing groups at one end of 
the substrate (acetates, acids or alcohols). Geranyl acetate, undecanoic acid and other similar 
substrates would in theory have a functional group that could also interact in a similar manner 
and position.  
The pseudoionone molecule appears to be completely enclosed in the active site (Figure 
8), suggesting CYP268A2 has crystallised in the ‘closed form’ of the P450 [67]. Indeed, the 
enzyme completely encloses the substrate, showing no access to the substrate channel from the 
surface (Figure S11a). The active site residues (12 within 4 Å of the substrate, Figure 7c) 
together create a linear substrate binding pocket which seems likely to preferentially exclude 
the cis form of pseudoionone, which was also present in the crystallisation conditions but not 
observed binding in the solved structure. This further supports the product formation data, 
which has shown the enzyme preferentially hydroxylates the trans isomer of pseudoionone at 
the ω terminus from the carbonyl group. The only significant vacant space in the active site is 
near the heme, where there is room to accommodate a larger group which would rationalise the 
binding of phenyltoluene-like molecules and the phenylimidazole inhibitors.  
Two obvious water channels from the surface to the heme are observed and these are 
similar to those found in other CYPs. One, referred to as the ‘water channel’, approaches the 
coordinating cysteine from the proximal face of the enzyme, beginning from the base of the B-
C loop (Figure S12), while the other, on the distal side between the E, F and I helices, is the 
‘solvent channel’ [68]. Residues of the I helix, including the acid Asp263, participate in the 
hydrogen bonding network, by interacting directly with the water molecules, that comprises 
the solvent channel (Figure S13). The water channel is thought to be involved in active site 
solvation, and the solvent channel to be responsible for proton relay [68]. 
Comparison of the structure of the enzyme to the close relative CYP124A1 was made 
(Figure 7b). The active site of CYP124A1 accommodates larger substrates (~C16), and a 
phytanic acid-bound structure is available (2WM4) [21]. This structure shows the substrate 
bound in a similar manner to that of pseudoionone close to the heme, but the carboxylate end 
of the phytanic acid curves into a pocket that is not available in the CYP268A2 enzyme, as a 
result of the presence of a tryptophan residue, Trp90 (Figure 7d). Both the Gln209 and Ser99 
residues are not present in CYP124, replaced by a serine group (Ser216, which is shifted further 
away from the active site) and a phenylalanine (Phe107) respectively, neither of which interact 
electrostatically with the longer phytanic acid. Furthermore the hydrophilic Gln100 is not 
present in CYP124A1 (replaced by Gly108) and the Thr264 (of the acid-alcohol pair) is flipped 
(Thr271 in CYP124A1). The position of Thr264 also affects the commonly conserved 
hydrogen bond between the alcohol and the nearby alanine carbonyl (Ala260 in CYP268A2, 
Ala267 in CYP124A1), with the bond distance in CYP268A2 2.7 Å compared to 3.7 Å in 
CYP124A1 (Figure S14). The position of the threonine in CYP268A2 matches the orientation 
of the equivalent residue in camphor-bound P450cam, which has a distance of 2.5 Å [69]. The 
tightness of this hydrogen bond is hypothesised to affect solvent access to the active site of the 
enzyme: in the closed position solvent access is restricted, in the open form allowed [70].  
The crystal structure of pseudoionone-bound CYP268A2 provides important insight 
into the substrate selectivity of these enzymes. The comparison with related CYP124A1 from 
M. tuberculosis provides an understanding on how these enzymes have evolved to modify their 
substrate selectivity. M. marinum also contains a gene encoding a CYP124A1 protein (84 % 
similarity to CYP124A1 from M. tuberculosis), and both could have evolved from a common 
ancestor. At some point in time the progenitors of the CYP268A2 and CYP124A1 enzymes 
may have had an overlapping function, providing genetic redundancy, and hence CYP268A2 
may only be maintained in the larger genome of the less immuno-challenged organism. 
However, our data suggest that CYP268A2 would support a more varied range of substrate 
hydroxylation in the native system than CYP124A1. Along with other protein encoding genes 
the broad substrate range of the CYP268A2 system potentially aids M. marinum in surviving 




The larger CYP complement of M. marinum contains several CYP families, including CYP268, 
which are widespread across Mycobacterium species but are absent in M. tuberculosis. The 
characterisation of CYP268A2 demonstrates that the selectivity and versatility of these 
enzymes can vary significantly even where there is structural and sequence similarity in the 
active site. CYP268A2 is the first member of this family to be characterised, and the substrate 
range of the enzyme reported here is broad with several molecules binding with high affinity. 
The successful hydroxylation of a long chain branched acetate and ketone demonstrates activity 
can be efficiently reconstituted with non-native electron transfer proteins including a [2Fe-2S] 
ferredoxin. This will assist with future attempts to identify the native electron transfer proteins. 
The substrate binding and turnover data presented here may be only the first of a broader range 
of molecules that can be oxidised by CYP268 family members. Further, the crystallisation and 
structural analysis rationalises the observed catalytic activity and forms the basis for any future 
attempt to improve it. Finally, potential azole inhibitors were identified for the enzyme, which 
bind to the heme iron. As CYP268 family members are present across a range of 
Mycobacterium species including human pathogens this could form the basis of future inhibitor 
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Tables and Figures 
Table 1: Spin state shift and dissociation constants of CYP268A2 with a variety of substrates, 
presented in descending order of magnitude of the type I spin state shift. The spin state shifts 
of a range of additional substrates are listed in Table S2.  
CYP268A2 substrates Spin state 
shift (% HS) 
Kd (µM) 
geranyl acetate 80 8.5 ± 1.9 
pseudoionone 80 3.6 ± 0.6 
farnesol 75 0.8 ± 0.2 
farnesyl acetate 75 5.1 ± 1.9 
10-undecenoic acid 70 1.6 ± 0.2 
undecanoic acid 70 1.1 ± 0.5 
capric acid 65 1.1 ± 0.5 
4-phenyltoluene 55 13 ± 2.4 
geraniol 55 7.9 ± 1.6 
lauric acid 55 270 ± 36 
linalyl acetate 55 110 ± 25 
neryl acetate 30 106 ± 29 
 
  
Table 2: Crystal refinement data for CYP268A2 from M. marinum (PDB: 6BLD) 
Data collection statisticsa  
Wavelength  0.95370 
Unit cell a = 154.76 b = 44.726 c = 57.727         
α = 90  β = 100.84 γ = 90 
Space group  C2  
Number of molecules in asymmetric unit  1 
Resolution 2.00 – 42.91 (2.00 – 2.05)b  
Number of unique reflections 26452 (1743) 
Completeness  99.2 (89.4)  
Redundancy  7.4 (7.0)  
(I)/[σ(I)] 9.7 (2.0)  
Rmerge (all I+ and I-) 0.130 (0.742) 
Rpim (all I+ and I-) 0.071 (0.411) 
CC(1/2) 0.997 (0.768) 
Rwork 19.96% 
Rfree 24.79% 
% solvent 42.89 
Number of residues modelled  413 
RMS deviation from restraint values 
Bond lengths  0.002 
Bond angles 0.551 
Ramachandran analysis 
Most favoured 98.06% 
Additionally allowed 1.94% 
 
a Data collected from one crystal 




Figure 1: Phylogenetic tree of the CYP268 family. Included are some members of the CYP124 
and CYP142 families, both of which have been predominately found in Mycobacterium 
species. The grouping shows that CYP268A2 is closely related to members of the 268 family, 
with significant sequence similarity to the 124 family (all above 40%) and the 142B subfamily 
(43% to 142B1). CYP124G1, which does not cluster with the remainder of the 124 family, has 
41% similarity to CYP268A2. Percentage identities can be found in Table S1. The tree was 
drawn to scale, with branch lengths measured in the number of substitutions per site. Scale 
measures number of substitutions per site.  
  
 
Figure 2: CYP268A2 (black, A419) in the reduced form (blue, A412), bound to CO (red, A449), 
showing the characteristic absorbance at ~450 nm. The shoulder at 420 nm in the ferrous-CO 










Figure 4: CYP268A2 binding constant analysis with the substrates A) pseudoionone B) 
geranyl acetate C) 4-phenyltoluene D) undecanoic acid E) 1-phenylimidazole (peak to trough 





Figure 5: (a) GC trace of the in vivo and in vitro turnovers of CYP268A2 with geranyl acetate 
(b) in vivo turnover with pseudoionone monitored over 24 hours. Identification of isomer peaks 
was done by retention time comparison with neryl acetate (cis) and geranyl acetate (trans), 
where the cis form had the shorter retention time. 
  
 
Figure 6: Hydroxylation products of CYP268A2. *In each, the hydroxylation at the terminal 
end would have generated a stereo-centre at the ω-1 carbon. However in vivo the 
hydrogenation occurred after the hydroxylation, and as a result the stereo-selectivity of the 





Figure 7: (a) M. marinum CYP268A2 (green) with pseudoionone bound (yellow), showing 
the composite omit 2F o − F c electron density at σ = 1.5 (blue mesh) of the pseudoionone in 
the active site (b) CYP268A2 (green) overlaid with M. tb CYP124A1 (blue) with phytanic 
acid (orange) bound, showing the conserved P450 helices[55] (c) CYP268A2 active site 
region showing side chains of amino acids within 5Å of the pseudoionone molecule. There 
are 12 residues within 4 Å: S99, Q100, L103, L187, L205, Q209, L256, V259, A260, T264, 
F311 and F408. The terminal carbonyl of the pseudoionone has polar contacts (red) with the 
amine group of Q209 and the hydroxyl group of S99 (d) the active site region showing side 
chains of amino acids from both enzymes within 5Å of the substrate molecules (CYP268A2 
labels in black, CYP124A1 blue). 
  
 
Figure 8: CYP268A2 (green) with the inner surface cavity of the peptide enclosing the 
pseudoionone (yellow). There is a small empty cavity near the heme.  
